Table 3 Baseline E-RS scores, overall and by GOLD group
RS-Totala | RS-Breathlessnessb | RS-Cough & Sputumc | RS-Chest Symptomsd | |
|---|---|---|---|---|
mean (SD) | mean (SD) | mean (SD) | mean (SD) | |
All patients | ||||
Placebo (n = 578) | 12.4 (6.5) | 6.3 (3.6) | 3.4 (1.9) | 2.7 (2.0) |
Aclidinium 400 μg BID (n = 583) | 12.7 (6.8) | 6.4 (3.7) | 3.5 (1.9) | 2.9 (2.1) |
Total (n = 1161) | 12.6 (6.6) | 6.3 (3.6) | 3.4 (1.9) | 2.8 (2.0) |
GOLD Group A | ||||
Placebo (n = 52) | 4.6 (3.2) | 2.0 (1.7) | 1.6 (1.3) | 0.9 (1.2) |
Aclidinium 400 μg BID (n = 42) | 6.0 (5.2) | 2.3 (2.7) | 2.3 (1.8) | 1.4 (1.7) |
Total (n = 94) | 5.2 (4.3) | 2.1 (2.2) | 2.0 (1.6) | 1.1 (1.5) |
GOLD Group B | ||||
Placebo (n = 270) | 13.1 (5.9) | 6.5 (3.2) | 3.6 (1.8) | 3.0 (1.8) |
Aclidinium 400 μg BID (n = 296) | 13.1 (6.5) | 6.4 (3.5) | 3.6 (1.9) | 3.1 (2.0) |
Total (n = 566) | 13.1 (6.2) | 6.4 (3.3) | 3.6 (1.8) | 3.1 (1.9) |
GOLD Group C | ||||
Placebo (n = 20) | 6.5 (4.4) | 3.0 (2.1) | 2.0 (1.6) | 1.5 (1.5) |
Aclidinium 400 μg BID (n = 22) | 6.0 (3.4) | 2.3 (1.7) | 2.4 (1.5) | 1.3 (1.2) |
Total (n = 42) | 6.2 (3.9) | 2.6 (1.9) | 2.2 (1.6) | 1.4 (1.4) |
GOLD Group D | ||||
Placebo (n = 236) | 13.9 (6.4) | 7.3 (3.5) | 3.6 (1.8) | 2.9 (2.0) |
Aclidinium 400 μg BID (n = 223) | 14.2 (6.5) | 7.5 (3.4) | 3.6 (2.0) | 3.2 (2.1) |
Total (n = 459) | 14.0 (6.5) | 7.4 (3.5) | 3.6 (1.9) | 3.0 (2.1) |